Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
Nov 22, 2024
BioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingVIEW RELEASE
Nov 21, 2024
BioXcel Therapeutics Announces Proposed Public OfferingVIEW RELEASE
Nov 14, 2024
BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Dec 03, 2024 11:51 AM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
0.4201
CHANGE
-0.01 (-2.33%)